Skip to main content

Bonsity Side Effects

Generic name: teriparatide

Medically reviewed by Last updated on Apr 4, 2023.

Note: This document contains side effect information about teriparatide. Some dosage forms listed on this page may not apply to the brand name Bonsity.

Applies to teriparatide: subcutaneous solution.

Serious side effects of Bonsity

Along with its needed effects, teriparatide (the active ingredient contained in Bonsity) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking teriparatide:

More common

Less common

Incidence not known

Other side effects of Bonsity

Some side effects of teriparatide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to teriparatide: subcutaneous solution.


The more commonly reported side effects have included arthralgia, pain, and nausea.


Rare (less than 0.1%): Anaphylaxis, possible allergic events soon after injection (e.g., acute dyspnea, oro/facial edema, generalized urticaria, chest pain, edema (mainly peripheral)

Postmarketing reports: Drug hypersensitivity, angioedema, urticaria[Ref]


Cases of bone tumor and osteosarcoma have been reported during the postmarketing period; however, an increased risk of osteosarcoma was not observed in observational studies. Two osteosarcoma surveillance safety studies (US claims-based database studies) designed to assess the incidence rate of osteosarcoma showed 3 osteosarcoma cases among 379,283 patients and zero cases among 153,316 patients receiving this drug. A similar risk for osteosarcoma has been observed with comparators. The interpretation of these results suggests caution as data sources do not allow for complete measurement and control for confounders.[Ref]

Frequency not reported: Osteosarcoma[Ref]


Frequency not reported: Urolithiasis


Common (1% to 10%): Hypotension, hypertension, palpitations, chest pain, angina pectoris

Uncommon (0.1% to 1%): Tachycardia, cardiac murmur

Frequency not reported: Peripheral edema[Ref]


Common (1% to 10%): Nausea, vomiting, hiatus hernia, gastro-esophageal reflux disease, constipation, diarrhea, dyspepsia, gastrointestinal disorder, tooth disorder

Uncommon (0.1% to 1%): Hemorrhoids[Ref]


Very common (10% or more): Pain in limb, arthralgia (10%)

Common (1% to 10%): Muscle cramps, neck pain, leg cramps

Uncommon (0.1% to 1%): Myalgia, arthralgia, back cramp/pain

Postmarketing reports: Muscle spasms of the leg or back[Ref]

Nervous system

Common (1% to 10%): Dizziness, headache, sciatica, syncope[Ref]


Common (1% to 10%): Dyspnea, rhinitis, cough increased, pharyngitis, pneumonia

Uncommon (0.1% to 1%): Emphysema[Ref]


Common (1% to 10%): Rash, sweating increased[Ref]


Frequency not reported: Transient hypoparathyroidism[Ref]


Common (1% to 10%): Anemia[Ref]


Common (1% to 10%): Mild and transient injection site events (e.g., pain, swelling, erythema, localized bruising, pruritus, minor bleeding at injection site)

Uncommon (0.1% to 1%): Injection site erythema, injection site reaction[Ref]


Common (1% to 10%): Hypercholesterolemia

Uncommon (0.1% to 1%): Hypercalcemia (greater than 2.76 mmol/L), hyperuricemia, weight gain, alkaline phosphatase increase

Postmarketing reports: Calciphylaxis, worsening of previously stable cutaneous calcification[Ref]


Very common (10% or more): Pain (21%)

Common (1% to 10%): Vertigo, fatigue, asthenia, syncope[Ref]


Common (1% to 10%): Depression, insomnia[Ref]


Uncommon (0.1% to 1%): Urinary incontinence, polyuria, micturition urgency, nephrolithiasis

Rare (less than 0.1%): Renal failure/impairment[Ref]

Frequently asked questions


1. Product Information. Forteo (teriparatide). Lilly, Eli and Company. 2002.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.